Objectives: The aim of this study was to research the frequency of the Babinski-2 sign in patients with hemifacial spasm as well as the correlation of Babinski-2 sign with clinical presentation, severity and treatment response to the application of botulinum toxin. Furthermore, the study researched correlation of Babinski-2 signs with the quality of life of patients with hemifacial spasm. Study outline: Correlation study. Participants and methods: The study was conducted from 9th June 2015 to 31st May 2016 in patients with hemifacial spasm treated with botulinum toxin through the application of botulinum toxin at the Clinic of Neurology at Clinical Hospital Center Osijek. A survey designed for the purpose of this study was used to gather demographic information and data related to hemifacial spasm. The survey was used to gather the information related to age, gender and duration of the disorder, the clinical presentation and the existence of neurovascular conflict. Jankovic Rating Scale (JRS) was used to determine the stage of the hemifacial spasm, and the Short Form-36 (SF-36) questionnaire was used to determine the quality of life. Tests were conducted in two parts, before and two to four weeks after the application of botulinum toxin. Results: We analyzed 13 patients. Positive Babinski-2 sign was found in 6 patients. There was no statistically significant correlation between the presence of Babinski-2 characteristics with severity of hemifacial spasm, clinical presentation, age, gender, duration of the disorder, and the therapeutic response to the application of botulinum toxin. Correlation was not statistically significant in the presence of Babinski-2 characteristics with the quality of life of patients with hemifacial spasm. Conclusion: It can be concluded that a positive Babinski-2 sign is a good clinical evidence to assist in the diagnosis of hemifacial spasm, but should not be seen as a definitive diagnostic criterion. We did not notice the impact of Babinski-2 sign on the clinical presentation, treatment response, nor the quality of life in patients with hemifacial spasm.